Pipeline & Launch Brand Alerts — July 2026
We tracked 26 pharma news catalysts in July across approvals, new indication approvals, positive Phase 3 readouts and M&A. Here are the updates that matter most — led by tulisokibart, zasocitinib and Utebzi.
At Athena BDA we publish a monthly newsletter for clients summarising the highest-priority FDA approvals and late-stage pipeline developments across pharma.
In July, we tracked 26 significant updates — including approvals, positive Phase 3 readouts, NDA submissions and M&A. Below are our top-priority selections as Hot Tips.
Hot Tip #1 — Tulisokibart | Merck
Merck announced that tulisokibart met the primary and key secondary endpoints in a Phase 3 induction study for patients with moderately to severely active ulcerative colitis. The anti-TL1A antibody, acquired through an $11 billion buyout of Prometheus, demonstrated significant clinical remission at week 12 and is positioned to compete against established therapies like AbbVie’s Skyrizi and Takeda’s Entyvio.
Athena BDA insight: Priority Score 1 — our lead hot tip this month. This is a key drug in Merck’s push to re-establish itself in immunology, underlined by an immunology team of over 50 stakeholders largely focused on this asset.
Hot Tip #2 — Zasocitinib | Takeda
Takeda’s TYK2 inhibitor zasocitinib met its primary endpoint in Phase 3 testing, with over 35% of plaque psoriasis patients achieving complete skin clearance compared to approximately 14% for BMS’s Sotyktu. The company expects to launch the therapy in the first half of 2027, where it will also face competition from Alumis and J&J’s recently approved Icotyde.
Athena BDA insight: Priority Score 1 — strong head-to-head data versus Sotyktu, with over 30 stakeholders confirmed as working on the launch.
Hot Tip #3 — Utebzi | GSK / Spero
GSK and Spero received FDA approval for Utebzi as the first oral carbapenem antibiotic for adults with complicated urinary tract infections, following Phase 3 data demonstrating non-inferiority to intravenous Primaxin. The drug provides an at-home alternative to hospital-based infusions and is expected to launch in the U.S. by the end of 2026.
Athena BDA insight: Priority Score 2 — adds to the momentum behind GSK’s Anti-Infectives portfolio, with Blujepa also recently approved for uncomplicated UTIs and expansion into gonorrhoea underway.
What else moved this month?
- A novel Fc-free CD40L inhibitor reported positive Phase 3 data in systemic lupus erythematosus, showing statistically significant reductions in disease activity and improvements in severe flare control at week 48.
- An oral orexin receptor 2 agonist improved daily functioning, cognition and nighttime sleep quality in narcolepsy type 1, and is now under regulatory review in multiple markets.
- An oral PCSK9 inhibitor delivered LDL-C reductions of up to 65% in patients with diabetes without worsening glycemia, positioning it as a potential oral alternative to injectable cholesterol therapies.
- A GLP-1/glucagon dual agonist showed 16.6% weight loss and a 63% reduction in liver fat in Phase 2 metabolic data, though GI tolerability remains a competitive question against established obesity therapies.
Want the full July analysis — including drug names, sales projections, source links and commercial-readiness insight? It’s all available inside the Athena BDA Pharma Insights Hub.